David Musket Net Worth

The estimated Net Worth of David B Musket is at least $527 Tisíc dollars as of 7 August 2024. Mr. Musket owns over 34,000 units of Capricor Therapeutics Inc stock worth over $341,473 and over the last 10 years he sold CAPR stock worth over $185,292. In addition, he makes $0 as Independent Director at Capricor Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Musket CAPR stock SEC Form 4 insiders trading

David has made over 10 trades of the Capricor Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 34,000 units of CAPR stock worth $47,260 on 7 August 2024.

The largest trade he's ever made was buying 70,962 units of Capricor Therapeutics Inc stock on 21 January 2015 worth over $249,786. On average, David trades about 10,725 units every 158 days since 2015. As of 7 August 2024 he still owns at least 81,692 units of Capricor Therapeutics Inc stock.

You can see the complete history of Mr. Musket stock trades at the bottom of the page.

David Musket biography

David B. Musket is Independent Director of CAPRICOR THERAPEUTICS, INC. . He joined the Capricor Board of Directors in 2012 and is a member of the Audit Committee and the Compensation Committee. Mr. Musket has vast experience in strategic finance and has been following developments in the pharmaceutical and medical device industries for over 30 years. Mr. Musket began his investment career as an equities research analyst at Goldman Sachs & Co. following the pharmaceutical industry. In 1991 he founded Musket Research Associates, a venture banking firm focused exclusively on emerging healthcare companies. In 1996 he co-founded ProMed Management, a healthcare-focused investment partnership. He is still actively involved with both of these entities. He has served on the boards of several private and public companies throughout his career, and is currently on the board of privately held TherOx, Inc., a medical device company. From 1999 to 2007, Mr. Musket served on the board of directors of publicly traded Conor MedSystems, Inc., a medical device company sold to Johnson & Johnson in 2007 for $1.4 billion. Mr. Musket holds a Bachelor of Arts degree in Biology and Psychology from Boston College.

How old is David Musket?

David Musket is 57, he's been the Independent Director of Capricor Therapeutics Inc since 2013. There are 11 older and 6 younger executives at Capricor Therapeutics Inc. The oldest executive at Capricor Therapeutics Inc is Louis Grasmick, 90, who is the Independent Director.

What's David Musket's mailing address?

David's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121.

Insiders trading at Capricor Therapeutics Inc

Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo... a Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.

What does Capricor Therapeutics Inc do?

capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has

Complete history of Mr. Musket stock trades at Capricor Therapeutics Inc

Capricor Therapeutics Inc executives and stock owners

Capricor Therapeutics Inc executives and other stock owners filed with the SEC include:

• Karen G. Krasney,
  Exec. VP, Gen. Counsel & Sec.
• Anthony J. Bergmann M.B.A.,
  CFO & Corp. Treasurer
• Karen Krasney,
  Executive Vice President, General Counsel
• Linda Marban,
  President, Chief Executive Officer, Director
• Dr. Linda Marbán,
  Co-Founder, Pres, CEO & Director
• Dr. Frank Isaac Litvack FACC, M.D.,
  Exec. Chairman
• Dr. Frank Isaac Litvack M.D., FACC,
  Exec. Chairman
• Joshua Kazam,
  Director
• David Musket,
  Independent Director
• Louis Manzo,
  Independent Director
• Louis Grasmick,
  Independent Director
• George Dunbar,
  Independent Director
• Earl Collier,
  Independent Director
• Deborah Ascheim,
  Chief Medical Officer
• Rachel Smith,
  Vice President - Research & Development
• Luis Rodriguez-Borlado,
  Vice President - Regenerative Therapies
• Houman Hemmati,
  Vice President - Medical & Clinical Development, New Therapies
• Thomas Copmann,
  Vice President - Regulatory Affairs and Drug Development
• Anthony Bergmann,
  Chief Financial Officer, Principal Accounting Officer
• Frank Litvack,
  Independent Executive Chairman of the Board
• Catherine Lee Kelleher,
  Consultant
• Dr. Deborah D. Ascheim,
  Consultant
• Dr. Eduardo Marbán,
  Co-Founder & Chairman of Scientific Advisory Board
• Leland Gershell,
  CHIEF FINANCIAL OFFICER
• John Edward A.Edward St. Jo...,
  
• Sinai Medical Center Cedars,
  10% owner
• Xavier Avat,
  
• Philip J Gotwals,
  
• Paul Gisbert Auwaerter,
  
• Eduardo Marban,
  10% owner
• Gregory W Schafer,
  Director
• Mike Kelliher,
  
• Karimah Es Sabar,